Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 14(4), 241-146.
The authors reviewed two studies on humans. concluding that due to the “minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across India … these drugs are worthy of fast track clinical trial for treatment.”
They also noted that because HCQ is already approved for diabetes in India, and since diabetics are in the high-risk group for COVID-19 mortality, it should be further researched for use for them.
Here are some studies on the use of HCQ for diabetes:
- Quatraro et al (1990) – Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus: A new job for an old drug?
- Kang et al (2009) – Hydroxychloroquine: A diabetic drug in disguise?
- Wondafrash et al (2020) – Potential effect of hydroxychloroquine in diabetes mellitus: A systematic review on preclinical & clinical trial studies
